Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BNOEFNASDAQ:ENTXCVE:MPHNASDAQ:OHRP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNOEFBionomics$0.00-43.3%$0.00$0.00▼$0.06$4.45M1.86140,299 shs22,900 shsENTXEntera Bio$2.07-6.8%$1.63$0.52▼$3.35$59.62M1.7210,364 shs163,373 shsMPHMedicureC$1.09+10.1%C$1.14C$0.99▼C$1.80C$11.17M1.014,335 shs3,000 shsOHRPOHR Pharmaceutical$0.42$7.37$1.60▼$6.28$1.19M0.84180,228 shs21,218 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNOEFBionomics0.00%0.00%0.00%0.00%-77.33%ENTXEntera Bio+8.29%-3.06%+40.51%+158.14%+179.25%MPHMedicure0.00%-8.33%-13.91%-13.91%-23.85%OHRPOHR Pharmaceutical+0.24%+4.73%-59.13%-30.07%+175.70%Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new reportMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNOEFBionomicsN/AN/AN/AN/AN/AN/AN/AN/AENTXEntera Bio1.6024 of 5 stars3.53.00.00.03.30.00.0MPHMedicureN/AN/AN/AN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNOEFBionomicsN/AN/AN/AN/AENTXEntera Bio3.00Buy$10.00383.09% UpsideMPHMedicureN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/ACurrent Analyst RatingsLatest BNOEF, ANP, MPH, ENTX, and OHRP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2024ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNOEFBionomicsN/AN/AN/AN/AN/AN/AENTXEntera Bio$130K458.58N/AN/A$0.36 per share5.75MPHMedicureC$22.94M0.49C$0.44 per share2.49C$2.10 per share0.52OHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNOEFBionomicsN/AN/A0.00∞N/AN/AN/AN/AN/AENTXEntera Bio-$8.89M-$0.31N/AN/AN/AN/A-101.78%-83.90%5/3/2024 (Estimated)MPHMedicureC$1.08MC$0.0912.11∞N/A4.71%5.04%2.49%5/24/2024 (Estimated)OHRPOHR Pharmaceutical-$13.23MN/A0.00∞N/AN/A-75.46%-71.18%N/ALatest BNOEF, ANP, MPH, ENTX, and OHRP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/2024Q4 2023ENTXEntera Bio-$0.08-$0.07+$0.01-$0.07N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNOEFBionomicsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AMPHMedicureN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNOEFBionomicsN/AN/AN/AENTXEntera BioN/A10.3210.32MPHMedicure2.862.281.29OHRPOHR PharmaceuticalN/A3.733.73OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNOEFBionomicsN/AENTXEntera Bio14.11%MPHMedicure23.10%OHRPOHR Pharmaceutical10.70%Insider OwnershipCompanyInsider OwnershipBNOEFBionomicsN/AENTXEntera Bio8.90%MPHMedicure26.99%OHRPOHR Pharmaceutical12.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBNOEFBionomicsN/A1.31 billionN/ANot OptionableENTXEntera Bio1728.80 million26.24 millionOptionableMPHMedicureN/A10.25 millionN/ANot OptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionableBNOEF, ANP, MPH, ENTX, and OHRP HeadlinesSourceHeadlinePharmaceutical Stocksbenzinga.com - April 14 at 8:00 AMCYCC Cyclacel Pharmaceuticals, Inc.seekingalpha.com - March 17 at 4:20 PMSun Pharmaceutical Industries Ltd.moneycontrol.com - February 3 at 8:52 AMAI Advances Pharmaceutical Packaging Inspectiondesignnews.com - May 22 at 9:22 AMThe OHRP and SUPPORT — Another Viewnejm.org - April 21 at 3:16 PMWorking at the Smithsoniansi.edu - February 23 at 5:49 PMOHR Pharmaceutical (OHRP) is now in Oversold Territoryca.finance.yahoo.com - September 12 at 11:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBionomicsOTCMKTS:BNOEFBionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Entera BioNASDAQ:ENTXEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.MedicureCVE:MPHMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.OHR PharmaceuticalNASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.